Abstract
Purpose
The aim of this meta-analysis is to evaluate whether the combination therapy with gonadotrophin-releasing hormone agonist (GnRHa) and recombinant human growth hormone (rhGH) are effective in the treatment of children with idiopathic short stature (ISS) and normal timed puberty by interrogating data from clinical controlled trials.
Methods
Literature retrieval, trail selection, data abstraction and quality assessment were completed independently by two authors. STATA software (version 14.1) was used for data analyses.
Results
This meta-analysis was conducted based on 8 (4 randomized and 4 non-randomized) controlled trials. A total of 245 ISS children with normal timed puberty were financially analyzed. Overall, combination therapy with GnRHa and rhGH can slightly increase final height by 3.70 and 3.43 cm compared with GH treatment alone and no treatment, final height standard deviation score (FHSDS) by 0.10 and 0.22, final height minus predicted adult height (FH-PAH) by 1.5 and 5.32 cm, final height minus predicted adult height (FH-TH) by 7.70 and 4.32 cm, respectively. Subgroup and meta-regression analyses revealed that study type, sample size, GnRHa duration, and percentage of boys were potential sources of between-trial heterogeneity. There was a low probability of publication bias for above comparisons, as indicated by Egger’s tests.
Conclusions
Our meta-analytical findings indicate that the combination therapy with GnRHa and rhGH can slightly increase the final height of ISS children with normal timed puberty, and the effect was not more obvious than GH alone. We do not recommend the combination therapy as a routine treatment for ISS.
Trial registration number
CRD42019133438
Similar content being viewed by others
References
S. Jafari-Adli, M. Qorbani, R. Heshmat, S.H. Ranjbar, E. Taheri, M.E. Motlagh, M. Noorozi, O. Safari, G. Shafiee, F. Rezaei, S. Safiri, R. Kelishadi, Association of short stature with life satisfaction and self-rated health in children and adolescents: the CASPIAN-IV study. J. Pediatr. Endocrinol. Metab. 29(11), 1299–1306 (2016). https://doi.org/10.1515/jpem-2016-0215
P. Cohen, A.D. Rogol, C.L. Deal, P. Saenger, E.O. Reiter, J.L. Ross, S.D. Chernausek, M.O. Savage, J.M. Wit, I.S.S.C.W. participants, Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J. Clin. Endocrinol. Metab. 93(11), 4210–4217 (2008). https://doi.org/10.1210/jc.2008-0509
J.M. Wit, P.E. Clayton, A.D. Rogol, M.O. Savage, P.H. Saenger, P. Cohen, Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm. IGF Res 18(2), 89–110 (2008). https://doi.org/10.1016/j.ghir.2007.11.004
A. Deodati, S. Cianfarani, Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ 342, c7157 (2011). https://doi.org/10.1136/bmj.c7157
A.M. Ramos-Levi, M. Marazuela, Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls. Endocrine 60(2), 203–218 (2018). https://doi.org/10.1007/s12020-017-1492-1
E. Inzaghi, E. Reiter, S. Cianfarani, The challenge of defining and investigating the causes of idiopathic short stature and finding an effective therapy. Horm. Res. Paediatr. 92(2), 71–83 (2019). https://doi.org/10.1159/000502901
A. Deodati, E. Peschiaroli, S. Cianfarani, Review of growth hormone randomized controlled trials in children with idiopathic short stature. Horm. Res. Paediatr. 76(Suppl 3), 40–42 (2011). https://doi.org/10.1159/000330157
J. Bryant, L. Baxter, C.B. Cave, R. Milne, Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst. Rev. 3, CD004440 (2007). https://doi.org/10.1002/14651858.CD004440.pub2
J.F. Sotos, N.J. Tokar, Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit. Int. J. Pediatr. Endocrinol. 2014(1), 15 (2014). https://doi.org/10.1186/1687-9856-2014-15
V.L. Chulani, L.P. Gordon, Adolescent growth and development. Prim. Care 41(3), 465 (2014). 10.1016/j.pop.2014.05.002–487
J.C. Carel, E.A. Eugster, A. Rogol, L. Ghizzoni, M.R. Palmert, E.-L.G.A.C.C. Group, F. Antoniazzi, S. Berenbaum, J.P. Bourguignon, G.P. Chrousos, J. Coste, S. Deal, L. de Vries, C. Foster, S. Heger, J. Holland, K. Jahnukainen, A. Juul, P. Kaplowitz, N. Lahlou, M.M. Lee, P. Lee, D.P. Merke, E.K. Neely, W. Oostdijk, M. Phillip, R.L. Rosenfield, D. Shulman, D. Styne, M. Tauber, J.M. Wit, Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123(4), e752–e762 (2009). https://doi.org/10.1542/peds.2008-1783
K.C.J. Yuen, S. Llahana, B.S. Miller, Adult growth hormone deficiency: clinical advances and approaches to improve adherence. Expert Rev. Endocrinol. Metab. 14(6), 419–436 (2019). https://doi.org/10.1080/17446651.2019.1689119
J.C. Carel, Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Mol. Cell. Endocrinol. 254–255, 226–233 (2006). https://doi.org/10.1016/j.mce.2006.04.034
J. Carel, Can we increase adolescent growth? Eur. J. Endocrinol. 151(Suppl 3), U101-8 (2004). https://doi.org/10.1530/eje.0.151u101
G. Saggese, G. Cesaretti, S. Barsanti, A. Rossi, Combination treatment with growth hormone and gonadotropin-releasing hormone analogs in short normal girls. J. Pediatr. 126(3), 468–473 (1995)
A.M. Pasquino, I. Pucarelli, M. Roggini, M. Segni, Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J. Clin. Endocrinol. Metab. 85(2), 619–622 (2000). https://doi.org/10.1210/jcem.85.2.6387
J.A. Yanovski, S.R. Rose, G. Municchi, O.H. Pescovitz, S.C. Hill, F.G. Cassorla, G.B. Cutler Jr, Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N. Engl. J. Med. 348(10), 908–917 (2003). https://doi.org/10.1056/NEJMoa013555
L. Dunkel, Treatment of idiopathic short stature: effects of gonadotropin-releasing hormone analogs, aromatase inhibitors and anabolic steroids. Horm. Res. Paediatr. 76(Suppl 3), 27–29 (2011). https://doi.org/10.1159/000330150
R. Balducci, V. Toscano, A. Mangiantini, G. Municchi, F. Vaccaro, S. Picone, A. Di Rito, B. Boscherini, Adult height in short normal adolescent girls treated with gonadotropin-releasing hormone analog and growth hormone. J. Clin. Endocrinol. Metab. 80(12), 3596–3600 (1995). https://doi.org/10.1210/jcem.80.12.8530605
D. Lindner, J.C. Job, J.L. Chaussain, Failure to improve height prediction in short-stature pubertal adolescents by inhibiting puberty with luteinizing hormone-releasing hormone analogue. Eur. J. Pediatr. 152(5), 393–396 (1993)
J.C. Carel, F. Hay, R. Coutant, D. Rodrigue, J.L. Chaussain, Gonadotropin-releasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development. J. Clin. Endocrinol. Metab. 81(9), 3318–3322 (1996). https://doi.org/10.1210/jcem.81.9.8784090
C. Bouvattier, J. Coste, D. Rodrigue, C. Teinturier, J.C. Carel, J.L. Chaussain, P.F. Bougneres, Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. J. Clin. Endocrinol. Metab. 84(10), 3575–3578 (1999). https://doi.org/10.1210/jcem.84.10.6032
R. Lanes, P. Gunczler, Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin. Endocrinol. 49(2), 197–202 (1998)
D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009). https://doi.org/10.1136/bmj.b2535
J.P. Frindik, J. Baptista, Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Pediatrics 104(4 Pt 2), 1000–1004 (1999)
O. Ghai, V. Paul, A. Bagga. Essential Pediatrics. 7th ed. (CBS Publishers and Distributors Pvt. Limited, India, 2010)
M.B. Ranke, Towards a consensus on the definition of idiopathic short stature. Horm. Res. 45(Suppl 2), 64–66 (1996). https://doi.org/10.1159/000184851
W.A. Marshall, J.M. Tanner, Variations in the pattern of pubertal changes in boys. Arch. Dis. Child. 45(239), 13–23 (1970). https://doi.org/10.1136/adc.45.239.13
W.A. Marshall, J.M. Tanner, Variations in pattern of pubertal changes in girls. Arch. Dis. Child. 44(235), 291–303 (1969). https://doi.org/10.1136/adc.44.235.291
M. Crowther, W. Lim, M.A. Crowther, Systematic review and meta-analysis methodology. Blood 116(17), 3140–3146 (2010). https://doi.org/10.1182/blood-2010-05-280883
K. Slim, E. Nini, D. Forestier, F. Kwiatkowski, Y. Panis, J. Chipponi, Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J. Surg. 73(9), 712–716 (2003)
R. DerSimonian, R. Kacker, Random-effects model for meta-analysis of clinical trials: an update. Contemp. Clin. Trials 28(2), 105–114 (2007). https://doi.org/10.1016/j.cct.2006.04.004
J. Bowden, J.F. Tierney, A.J. Copas, S. Burdett, Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med. Res. Methodol. 11, 41 (2011). https://doi.org/10.1186/1471-2288-11-41
I. Benabbad, M. Rosilio, M. Tauber, E. Paris, A. Paulsen, L. Berggren, H. Patel, J.C. Carel, Phoenix Study, G., Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature. Endocr. Connect. 7(5), 708–718 (2018). https://doi.org/10.1530/EC-18-0137
S.A. van Gool, G.A. Kamp, H. Visser-van Balen, D. Mul, J.J. Waelkens, M. Jansen, L. Verhoeven-Wind, H.A. Delemarre-van de Waal, S.M. de Muinck Keizer-Schrama, G. Leusink, J.C. Roos, J.M. Wit, Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J. Clin. Endocrinol. Metab. 92(4), 1402–1408 (2007). https://doi.org/10.1210/jc.2006-2272
G.A. Kamp, D. Mul, J.J. Waelkens, M. Jansen, H.A. Delemarre-van de Waal, L. Verhoeven-Wind, M. Frolich, W. Oostdijk, J.M. Wit, A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. J. Clin. Endocrinol. Metab. 86(7), 2969–2975 (2001). https://doi.org/10.1210/jcem.86.7.7650
J.C. Job, J.E. Toublanc, F. Landier, Growth of short normal children in puberty treated for 3 years with growth hormone alone or in association with gonadotropin-releasing hormone agonist. Horm. Res. 41(5-6), 177–184 (1994). https://doi.org/10.1159/000183889
M.A. Magiakou, D. Manousaki, M. Papadaki, D. Hadjidakis, G. Levidou, M. Vakaki, A. Papaefstathiou, N. Lalioti, C. Kanaka-Gantenbein, G. Piaditis, G.P. Chrousos, C. Dacou-Voutetakis, The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J. Clin. Endocrinol. Metab. 95(1), 109–117 (2010). https://doi.org/10.1210/jc.2009-0793
K.O. Klein, P.A. Lee, Gonadotropin-releasing hormone (GnRHa) therapy for central precocious puberty (CPP): review of nuances in assessment of height, hormonal suppression, psychosocial issues, and weight gain, with patient examples. Pediatr. Endocrinol. Rev. 15(4), 298–312 (2018). https://doi.org/10.17458/per.vol15.2018.kl.GnRHaforCPP
R.H. Willemsen, D. Elleri, R.M. Williams, K.K. Ong, D.B. Dunger, Pros and cons of GnRHa treatment for early puberty in girls. Nat. Rev. Endocrinol. 10(6), 352–363 (2014). https://doi.org/10.1038/nrendo.2014.40
S. Li, X. Wang, Y. Zhao, W. Ji, J. Mao, M. Nie, X. Wu, Combined therapy with GnRH analogue and growth hormone increases adult height in children with short stature and normal pubertal onset. Endocrine 69(3), 615–624 (2020). https://doi.org/10.1007/s12020-020-02375-5
N. Khawaja, H. Owaineh, A. Batieha, O. Frahid, M. El-Khateeb, K.M. Ajlouni, The effect of gonadotropin-releasing hormone analogue on final adult height in children with idiopathic short stature. Med. Princ. Pract. 28(6), 509–516 (2019). https://doi.org/10.1159/000499929
H. Visser-van Balen, R. Geenen, J. Looij, J. Huisman, J.M. Wit, G. Sinnema, The views of young adults and their parents on hormone treatment for short stature in adolescence. Horm. Res. 69(3), 172–179 (2008). https://doi.org/10.1159/000112591
H. Visser-van Balen, R. Geenen, G.A. Kamp, J. Huisman, J.M. Wit, G. Sinnema, Long-term psychosocial consequences of hormone treatment for short stature. Acta Paediatr. 96(5), 715–719 (2007). https://doi.org/10.1111/j.1651-2227.2007.00235.x
M.R. Munafo, J. Flint, Meta-analysis of genetic association studies. Trends Genet 20(9), 439–444 (2004). https://doi.org/10.1016/j.tig.2004.06.014
Author contributions
Conceived and designed the article: L.W., Z.Z., W.N. Performed the experiments: B.Z., S.L., W.N. Analyzed the data: B.Z., S.L., Y.Y. Contributed materials/analysis tools: B.Z., J.W., Z.Z. Wrote and revised the paper: B.Z., T.Z., W.N., L.W. All authors read and approved the final manuscript prior to submission.
Funding
This research was supported by Public Service Development and Reform Pilot Project, Beijing Municipal Health Commission (BMR2019-11), Capital’s Funds for Health Improvement and Research (2020-2-2104), and Research Foundation of Capital Institute of Pediatrics (CXYJ-2021-08, QN-2020-09).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
About this article
Cite this article
Zhou, B., Liu, S., Wang, J. et al. A meta-analysis of combination therapy with gonadotrophin-releasing hormone agonist and growth hormone for children with idiopathic short stature and normal timed puberty. Endocrine 75, 698–708 (2022). https://doi.org/10.1007/s12020-021-02970-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02970-0